Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

J Am Coll Cardiol. 2016 Apr 5;67(13):1654-1656. doi: 10.1016/j.jacc.2016.01.043.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology*
  • Antithrombins / pharmacology
  • Cross-Over Studies
  • Dabigatran / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Drug Monitoring / methods
  • Drug-Related Side Effects and Adverse Reactions / therapy*
  • Female
  • Healthy Volunteers
  • Humans
  • Male
  • Middle Aged
  • Retreatment / methods*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antithrombins
  • idarucizumab
  • Dabigatran

Associated data

  • ClinicalTrials.gov/NCT01955720